Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol versus salmeterol in moderate-to-severe chronic obstructive pulmonary disease
2008-005146-23Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Indacaterol arm with Salmeterol arm (2 arms). Primary endpoint: Standardized FEV1 AUC from 5 minutes to 11 hours 45 minutes after morning dose at Day 84. Started Jan 2009; status: completed.
02
Drugs
indacaterolsalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-005146-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005146-23.